People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alphina Therapeutics, Inc. | — | Biotechnology | Series B | $17.0M | $541K | 2021 |
| Modifi Biosciences, Inc. | — | Biotechnology | Series A | $11.5M | $4.9M | 2022 |
| CapeHaven Holding Company, LLC | — | Biotechnology | Seed | $1.4M | $3.9M | 2025 |
Ranjit L. Bindra at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ranjit L. Bindra on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin L. Rakin | 3 | 7 |
| Barbara J Fox | 1 | 1 |
| Colleen J Cuffaro | 1 | 1 |
| Nicholas J Galli | 1 | 1 |
| Kevin J Rakin | 1 | 1 |
| Matthew J Cohen | 1 | 1 |
| Ranjit J Bindra | 1 | 1 |
| Colleen L. Cuffaro | 1 | 1 |
| Anurag L. Agarwal | 1 | 1 |
| Stanley L. Choy | 1 | 1 |
| Michael L. Dillon | 1 | 1 |
| Kat L. Kayser-Bricker | 1 | 1 |
| Lucas L. De Breed | 1 | 1 |
| Seth L. Herzon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.